Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114881) titled 'Anlotinib Plus Camrelizumab and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective Phase II Trial' on Dec. 18, 2025.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The General Hospital of the Western Theater Command of the Chinese People's Liberation Army
Condition:
Esophageal cancer
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2025-12-22
Target Sample Size: study arm:56;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=296785
Publi...